Cancer Research and Treatment10.4143/crt.2016.069201749137-43Use of a High-Throughput Genotyping Platform (OncoMap) for <i>RAS</i> Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal CancerDalyong Kim, Yong Sang Hong, Jeong Eun Kim, Kyu-pyo Kim, Jae-Lyun Lee, Sung-Min Chun, Jihun Kim, Se Jin Jang, Tae Won Kim,,
Annals of Oncology10.1093/annonc/mdv523.17201526ix42156P High-throughput genotyping platform (OncoMap), a precise tool for predicting cetuximab efficacy in patients with metastatic colorectal cancerD. Kim, Y.S. Hong, J.E. Kim, K.-P. Kim, J.-L. Lee, J. Kim, S.J. Jang, T.W. Kim,
Clinical Colorectal Cancer10.1016/j.clcc.2016.07.0172017162e29-e37Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus ChemotherapyKensei Yamaguchi, Masahiko Ando, Akira Ooki, Frank Beier, Silke Guenther, Philipp von Hohnhorst, Eric Van Cutsem,
Annals of Oncology10.1093/annonc/mdw199.10201627ii3P-010 Next generation sequencing mutational analysis of primary and metastatic colorectal cancer samples in relationship to efficacy of cetuximab-based therapyR. Nemecek, J. Berkovcova, O. Slaby, M. Svoboda,,
Scientific Reports10.1038/s41598-017-17130-6201771Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RASJing Yang, Xinli Guo, Manni Wang, Xuelei Ma, Xiaoyang Ye, Panpan Lin,,
Value in Health10.1016/j.jval.2015.09.11872015187A460Cost-Effectiveness Analysis Of Cetuximab And Panitumumab For First Line Treatment Of Metastatic Colorectal Cancer (Mcrc) In Wt Ras Patients In SpainJ Suarez,
Annals of Oncology10.1093/annonc/mdz338.112201930vi116Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge TrialMasato Nakamura,,,
Annals of Oncology10.1093/annonc/mdw370.69201627vi172Association between HER2 amplification and cetuximab efficacy in patients with RAS wild-type metastatic colorectal cancerJ. Jeong, J. Kim, Y.S. Hong, D. Kim, J.E. Kim, S.Y. Kim, K.-P. Kim, T.W. Kim,,
Clinical Colorectal Cancer10.1016/j.clcc.2022.05.0052022213259-266Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 TrialHiroyuki Arai, Joshua Millstein, Yan Yang, Sebastian Stintzing, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Volker Heinemann, Heinz-Josef Lenz,
Clinical Colorectal Cancer10.1016/j.clcc.2013.10.001201413162-67Pilot Clinical Trial on the Efficacy of Prophylactic Use of Vitamin K1–Based Cream (Vigorskin) to Prevent Cetuximab-Induced Skin Rash in Patients With Metastatic Colorectal CancerFrancesco Pinta, Agostino Ponzetti, Rosella Spadi, Laura Fanchini, Marcello Zanini, Caterina Mecca, Cristina Sonetto, Libero Ciuffreda, Patrizia Racca,